Valeant Pharmaceuticals calls remaining $465.5 million 6½% notes

By Marisa Wong

Madison, Wis., Dec. 2 - Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem the remaining $465.5 million principal amount of its outstanding 6½% senior notes due 2016.

On Nov. 15 the company mailed a notice of redemption for $450 million principal amount of the 6½% notes, concurrent with the pricing of a new issue of senior notes.

Bank of New York Mellon Trust Co., NA is the trustee.

The specialty pharmaceutical company is based in Laval, Quebec. Its U.S. headquarters are in Bridgewater, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.